Clinical Trials
23
Active:2
Completed:4
Trial Phases
4 Phases
Phase 1:5
Phase 2:7
Phase 3:5
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (30.4%)Not Applicable
6 (26.1%)Phase 1
5 (21.7%)Phase 3
5 (21.7%)A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
Not Applicable
Recruiting
- Conditions
- Health Adult Subjects
- Interventions
- Biological: GR2303 injectionBiological: Placebo
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT07199270
- Locations
- 🇨🇳
Beijing Friendship hospital, Capital Medical University, Beijing, Beijing Municipality, China
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
Not Applicable
Not yet recruiting
- Conditions
- Allergic Rhinitis, Seasonal
- Interventions
- Biological: GR1802 injectionBiological: Placebo
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT07199257
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan university, Wuhan, Hubei, China
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
Not Applicable
Not yet recruiting
- Conditions
- Single Ascending DoseHealthy Subjects
- Interventions
- Biological: GR2301 injection
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT07190716
- Locations
- 🇨🇳
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality, China
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
Not Applicable
Recruiting
- Conditions
- Allergic Rhinitis, Seasonal
- Interventions
- Biological: GR1802 injectionBiological: Placebo
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT07154342
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan university, Wuhan, Hubei, China
Phase I Trial of GR1803 Injection in Patients With RRMM
Not Applicable
Completed
- Conditions
- Multiple Myeloma (MM)
- Interventions
- Drug: GR1803 injection
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT07102706
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found